Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 2/20 | 0.47 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | GLP1R | P43220 | 8/20 | 0.42 |
| ▸ | C3AR1 | Q16581 | 2/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.41 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.38 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.38 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.38 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.38 |
| ▸ | GNPAT | O15228 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7135222 | 1.00 | FOLH1 (0.47) | FOLH1SLC6A5GLP1RC3AR1DGAT1 | |
| SCHEMBL30914214 | 1.00 | FOLH1 (0.47) | FOLH1SLC6A5GLP1RC3AR1DGAT1 | |
| SCHEMBL25309372 | 1.00 | FOLH1 (0.47) | FOLH1SLC6A5GLP1RC3AR1DGAT1 | |
| SCHEMBL20797921 | 0.99 | FOLH1 (0.48) | FOLH1SLC6A5GLP1RC3AR1DGAT1 | |
| SCHEMBL19019936 | 0.99 | FOLH1 (0.48) | FOLH1SLC6A5GLP1RC3AR1DGAT1 | |
| SCHEMBL6974284 | 0.90 | FOLH1 (0.50) | FOLH1SLC6A5GLP1RC3AR1SLC15A2 | |
| SCHEMBL450379 | 0.90 | FOLH1 (0.50) | FOLH1SLC6A5GLP1RC3AR1SLC15A2 | |
| SCHEMBL29221101 | 0.89 | SLC6A5 (0.52) | FOLH1SLC6A5GLP1RDGAT1GNPAT | |
| SCHEMBL2928076 | 0.88 | SLC6A5 (0.50) | FOLH1SLC6A5GLP1RC3AR1SLC15A2 | |
| SCHEMBL21443609 | 0.87 | GLP1R (0.45) | FOLH1SLC6A5GLP1RC3AR1SLC15A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228958-A1 | TSP1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-4467561-A1 | TSP1 INHIBITOR | Daiichi Sankyo Company, Limited (JP) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023136342-A1 | TSP1 INHIBITOR | 第一三共株式会社 | 2023-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228958-A1 | TSP1 INHIBITOR | ANXA11, SERPINC1, NPR1 | FOLH1 1296/4885SLC6A5 285/4885GLP1R 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.